Leerink Partners cuts Madrigal Pharmaceuticals EPS forecast

Summary

Leerink Partners has lowered its FY2028 earnings per share estimate for Madrigal Pharmaceuticals (NASDAQ:MDGL) from $29.38 to $28.37. The consensus estimate for the company’s current full-year earnings is ($23.47) per share. Additionally, estimates for FY2029 earnings are set at $50.04 EPS. Despite the downgrade, several analysts maintain a ‘buy’ rating, with target prices ranging from $421.63 to $460.00. Madrigal’s stock recently traded down 0.2% to $337.41, with a market cap of $7.49 billion and a negative net margin of 54.68%.Market Beat

Impact Analysis

1. Business Overview Analysis

• Core Business Model: Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH). The company’s key revenue streams are derived from drug sales and potential milestone payments.
• Market Position: Madrigal is positioned as a leader in the MASH therapeutic space, with its lead candidate, Resmetirom, showing promise as the first FDA and EMA-approved treatment for MASH.Simplywall
• Recent Significant Events: Madrigal reported a narrower quarterly adjusted loss compared to the same period last year, indicating significant progress in its financial health.Reuters+ 2

2. Financial Statement Analysis

• Income Statement: Revenue growth is driven by the progress of Resmetirom, although the company currently operates at a loss. The recent quarterly loss per share of $1.90 is a significant improvement from the previous year’s $7.10 loss.Reuters Margins remain negative with a net margin of -54.68%.Market Beat
• Balance Sheet: The company has a market cap of $7.49 billion, reflecting investor confidence in its future prospects despite current losses. Detailed asset and liability data are not provided, but the high market cap suggests strong investor backing.Market Beat
• Cash Flow: Specific cash flow statements are not provided, but the improvement in quarterly losses and high market cap suggest robust operational cash management and potential future profitability.
• Key Financial Ratios:
• Profitability: Given the negative net margin, ROE and ROA are likely negative.
• Liquidity and Solvency: Detailed ratios are not provided, but the high market cap and investor backing suggest adequate liquidity and solvency.
• Efficiency: Data on asset turnover and inventory turnover are not available.

3. Impact and Opportunities

• Impact: The downgrade in EPS estimates for FY2028 reflects a more conservative view of short-term profitability, potentially influenced by market conditions or internal factors. However, the strong EPS estimates for FY2029 ($50.04) indicate long-term optimism.Market Beat Despite the downgrade, the stock’s slight dip by only 0.2% and maintained ‘buy’ ratings reflect continued investor confidence.Market Beat

4. Risks and Mitigation

• Risks: Potential delays in drug approval, market competition, and financial health in the short term.
• Mitigation: Continued progress in developing Resmetirom, strong investor backing, and strategic financial management.

Overall, while the short-term downgrade in EPS estimates presents a cautious outlook, the long-term prospects for Madrigal Pharmaceuticals remain strong, supported by significant investor confidence and promising drug development progress.